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A B S T R A C T
Purpose: To report a rare case of intraoperative suprachoroidal hemorrhage during Xen gel stent implantation
with accompanying surgical video and subsequent 6-month follow-up.
Observations: Our patient required incisional glaucoma surgery after inadequate pressure reduction with four
classes of topical medication, methazolamide, and selective laser trabeculoplasty. The patient underwent Xen gel
stent implantation and developed an intraoperative suprachoroidal hemorrhage, which was managed in the
operating room. The patient recovered his baseline visual acuity with a functioning bleb out to 6 months
postoperatively.
Conclusions and Importance: Micro-invasive glaucoma surgeries offer a new repertoire of surgical options, pur-
portedly with safer and less invasive techniques. Xen gel stent implantation may be a promising alternative to
traditional trabeculectomies and tube shunt implants, providing similar IOP lowering results with potentially
lower risk for complications. However, rare and severe complications such as suprachoroidal hemorrhage may
still occur. Recognizing a suprachoroidal bleed, particularly intraoperatively, will still be necessary to help
minimize the potential vision threatening sequelae often associated with this severe complication.
1. Introduction
Glaucoma is the leading cause of irreversible blindness in both the
United States and worldwide.1 The enduring gold standard for surgery
in primary open-angle glaucoma is trabeculectomy, which creates a
direct communication between the anterior chamber and the sub-
conjunctival space, bypassing the resistance of the trabecular outflow
system. Despite the efficacy of this technique and its longstanding use
as the surgical gold standard, it continues to be associated with com-
plications such as bleb leaks, subconjunctival fibrosis, and inconsistent
filtration rates.2 A rare but worrisome and vision threatening compli-
cation is suprachoroidal hemorrhage (SCH), which can occur in-
traoperatively or postoperatively. The pathophysiology of SCH is not
fully understood, but likely involves early hypotony, rupture of pos-
terior ciliary arteries, and subsequent hemorrhage.3 The outcome is
often devastating, with many patients reaching a final visual acuity of
no light perception.4
The desire to mitigate these potential complications has driven the
development of micro-invasive glaucoma surgery (MIGS). Because of
the less disruptive surgical technique, this new repertoire of glaucoma
procedures offers the potential for safer and more reliable intraocular
pressure (IOP) reduction when compared to traditional glaucoma fil-
tration surgeries.5 The Xen (Allergan, CA) gel stent is an ab-interno
MIGS device that shows promise in producing IOP reduction compar-
able to traditional glaucoma surgeries, but with potentially fewer
complications.1,6 However, the risk for complications still exists. To the
best of our knowledge, we report for the first time on a case of in-
traoperative suprachoroidal hemorrhage during Xen gel stent im-
plantation.
2. Case report
An 85-year-old Caucasian male was referred one year prior for un-
controlled glaucoma. On initial presentation, the patient had 20/20
vision with IOP of 24 mmHg in the right eye and 20/60 vision with IOP
of 35 mmHg in the left eye. The patient was being treated with three
topical glaucoma agents. After a fourth agent was added, the IOP in the
left eye remained in the mid-20s. Subsequently, an Ahmed glaucoma
drainage device was implanted. Three months post-operatively, the
patient had IOP of 8 mmHg and vision had recovered to 20/100. At 8-
months post-operatively, vision was 20/40 with IOP of 12 mmHg.
Unfortunately, the IOP in the right eye increased to 30 mmHg
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despite maximal medical therapy and selective laser trabeculoplasty
(SLT). The decision was made to have the patient undergo Xen im-
plantation with mitomycin C.
The patient underwent routine Xen implantation after pre-operative
injection of 20 μg of subconjunctival mitomycin C. After the standard
ophthalmic prep and draping procedure, a sideport blade was used to
fashion a paracentesis superotemporally. Preservative free lidocaine
was injected intracamerally. Healon was then injected to maintain the
anterior chamber. A clear corneal incision was constructed with a
keratome inferotemporally, taking care to avoid excessive interference
from the patient's prominent cheekbone.
The Xen was then deployed superiorly. At that time, the patient
noted discomfort and the chamber began to shallow but remained
formed. The main wound was secured with ReSure sealant. The eye was
monitored for approximately 20 minutes. The chamber remained
shallow with IOP around 25–30 mmHg, but the red reflex was main-
tained. The anterior chamber slowly stabilized and the viscoelastic was
carefully replaced with balanced salt solution. IOP was equilibrated to
approximately 30 mmHg at the end of the case. The retina was visua-
lized intra-operatively, but no definite suprachoroidal hemorrhage
could be immediately identified with the hazy view. Post-operative
drops were added and the eye was patched and shielded. Strict activity
precautions were given to the patient and family.
Please see accompanying video for intra-operative features.
Supplementary video related to this article can be found at https://
doi.org/10.1016/j.ajoc.2020.100600.
On post-operative day 1, the patient's pinhole vision was 20/70 with
IOP of 7 mmHg and slit-lamp exam showed a well-formed anterior
chamber. An inferonasal suprachoroidal hemorrhage was identified
outside of the inferonasal arcade. The patient was continued on the
difluprednate, polytrim, and atropine eye drops. At the 1-week post-
operative visit, vision was 20/50 with IOP of 10 mmHg and a stable
SCH, which steadily resolved without additional complication over the
ensuing 6 weeks.
At the 2-month post-operative visit, vision returned to 20/30 with
an unmedicated IOP of 16 mmHg and a well-formed superonasal bleb.
By the 6-month post-operative visit, the patient recovered to 20/25
vision with an unmedicated IOP of 14 mmHg and a well-formed su-
peronasal bleb.
3. Discussion
Glaucoma remains a leading cause of blindness, with under-diag-
nosis, under-treatment, and medication noncompliance being persistent
factors contributing to the disease burden.1 The advances in MIGS
procedures has sparked a renaissance in glaucoma management, di-
rected at earlier surgical intervention in order to improve IOP and re-
duce topical medication dependence. The potential for an improved
safety profile, more reproducible technique, and adjuvant use during
cataract surgery are compelling reasons to consider these new techni-
ques.
The design of the Xen gel stent aims to maximize these potential
benefits. The flexible and biocompatible material is meant to minimize
migration, erosion, and surrounding inflammatory response.6 The FDA-
approved device has a 6 mm length and 45 μm inner lumen diameter.
At physiologic aqueous humor flow rates, an outflow resistance of
6–8 mmHg is predicted by the Hagen-Poiseuille equation, theoretically
eliminating the risk for hypotony.7 Early results have been comparable
to traditional glaucoma surgeries in terms of IOP reduction and de-
creased dependency for topical medications. Four prospective, non-
comparative studies assessing Xen gel stent outcomes reported a mean
IOP reduction ranging from 25% to 42% and a mean reduction of to-
pical medication burden ranging from 1.6 to 2.9 classes.8,9 However,
instances of hypotony still occurred in most of these studies: the rates of
hypotony were 0%, 2.4% (1 eye), 15.4% (2 eyes), and 24.6% (16 eyes).
3 of these eyes were associated with a choroidal detachment, all of
which resolved with conservative medical management.
In the case described, although no obvious hypotony was noted
intraoperatively during the time of Xen implantation, it is possible that
some egress of ocular viscodispersive (OVD) agent through the main
wound may have lowered the IOP enough to predispose the patient to
the suprachoroidal hemorrhage. One may consider using a heavier
molecular weight OVD, such as Healon GV, for chamber maintenance
during implantation to reduce the possibility of IOP shifts during im-
plantation. However, meticulous removal of OVD would be necessary to
prevent a large post-operative IOP spike.
Only one case report in the literature so far has described su-
prachoroidal hemorrhage associated with Xen gel stent placement.10 In
that case, the patient experienced initial post-operative hypotony after
uncomplicated Xen implantation. On post-operative day two, the pa-
tient developed severe pain. The exam showed an IOP of 54 mmHg, a
shallow anterior chamber, and visual acuity of no light perception.
Ultrasound examination confirmed the presence of a SCH. Conservative
medical management was employed and a final visual acuity of hand
motion was reached in an eye with a presenting visual acuity of 20/25.
Unlike the previously presented case that ended in devastating vi-
sual consequences, our patient was able to reach his baseline vision
with a well-functioning Xen gel stent. Despite the poor visual outcome
in the previously published case report, we postulate that the slower
and more controlled flow rates with the Xen compared with traditional
trabeculectomy or glaucoma drainage device surgery could potentially
minimize the adverse effects in eyes that develop suprachoroidal he-
morrhage or choroidal effusions by limiting the IOP fluctuations and
the transscleral pressure gradient. More comparative data is needed to
determine if the rates and outcomes of these complications are sig-
nificantly improved when compared to traditional glaucoma surgeries,
but the presence of limited numerical hypotony that almost universally
self-resolves without invasive intervention is encouraging. Regardless,
the potential for SCH will persist in many intra-ocular procedures.
Keeping this in mind may allow for earlier detection and management
of SCH, potentially leading to better visual outcomes.
4. Conclusion
The new arsenal of MIGS procedures for the treatment of open-angle
glaucoma has offered the potential for safer and less-invasive techni-
ques. Xen gel stent implantation may achieve moderate IOP reduction
while exhibiting an improved safety profile. However, serious compli-
cations such as suprachoroidal hemorrhage can still occur. Early re-
cognition and prompt management will remain important in Xen gel
stent implantation, as well as other glaucoma procedures.
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